DSGN (Design Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


DSGN Design Therapeutics Inc DSGN
33 GF Score
Price $15.65
! 2 Warning Signs
View Full Analysis

What is Design Therapeutics OCF Margin %?

Design Therapeutics DSGN +6.68% 33 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates DSGN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 951 Biotechnology companies, Design Therapeutics ranks worse than 105152.37% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Design Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-16.43 Mil. Design Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Design Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Design Therapeutics's current OCF Yield % is -5.52%.

The historical rank and industry rank for Design Therapeutics's OCF Margin % or its related term are showing as below:


DSGN's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Design Therapeutics OCF Margin % Related Terms

Design Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Design Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Design Therapeutics OCF Margin % Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Design Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DSGN
33GF Score
Design Therapeutics Inc DSGN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Design Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Design Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-54.358/0
= %

Design Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.431/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Design Therapeutics (DSGN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Design Therapeutics and its competitors. According to the industry distribution chart, Design Therapeutics ranks #999999 out of 951 companies in the Biotechnology industry.
Is Design Therapeutics' OCF Margin % too high?
Design Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Design Therapeutics ranks #999999 out of 951 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Design Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Design Therapeutics' OCF Margin % compare to SPRY and GERN?
According to the Biotechnology industry distribution chart, Design Therapeutics ranks #999999 out of 951 companies for OCF Margin %. This places Design Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Design Therapeutics and its competitors. Design Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Design Therapeutics stock overvalued right now?
Design Therapeutics (DSGN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Design Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Design Therapeutics (DSGN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Design Therapeutics Business Description

Address 6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
33GF Score

Get the complete analysis for DSGN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.65
Price